KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Dividends Paid - Common (2020 - 2023)

Historic Dividends Paid - Common for Boston Scientific (BSX) over the last 4 years, with Q2 2023 value amounting to $14.0 million.

  • Boston Scientific's Dividends Paid - Common changed 0.0% to $14.0 million in Q2 2023 from the same period last year, while for Mar 2024 it was $14.0 million, marking a year-over-year decrease of 7454.55%. This contributed to the annual value of $28.0 million for FY2023, which is 4909.09% down from last year.
  • According to the latest figures from Q2 2023, Boston Scientific's Dividends Paid - Common is $14.0 million, which was down 0.0% from $14.0 million recorded in Q1 2023.
  • Boston Scientific's Dividends Paid - Common's 5-year high stood at $14.0 million during Q3 2020, with a 5-year trough of $13.0 million in Q4 2021.
  • Moreover, its 4-year median value for Dividends Paid - Common was $14.0 million (2020), whereas its average is $13.8 million.
  • Over the last 5 years, Boston Scientific's Dividends Paid - Common had its largest YoY gain of 0.0% in 2021, and its largest YoY loss of 714.29% in 2021.
  • Boston Scientific's Dividends Paid - Common (Quarter) stood at $14.0 million in 2020, then fell by 7.14% to $13.0 million in 2021, then changed by 0.0% to $13.0 million in 2022, then rose by 7.69% to $14.0 million in 2023.
  • Its Dividends Paid - Common was $14.0 million in Q2 2023, compared to $14.0 million in Q1 2023 and $13.0 million in Q4 2022.